Form 8-K · Current report
Boeing 8-K, filed Aug 28, 2026
- Filed
- CIK
- 0000012927
- Accession no.
- 0001628280-26-059427
Summary
Boeing entered into a new $3.0 billion 364-day revolving credit agreement with Citibank and JPMorgan as joint lead arrangers, replacing its prior 364-day facility. Boeing also amended its 2024 and 2023 five-year credit agreements to extend their terms by 365 days and require Boeing to maintain at least $5.0 billion of liquidity.
Key points
- Boeing's new $3.0 billion 364-day revolving credit agreement replaced a prior facility scheduled to terminate on August 24, 2026.
- The 2024 five-year credit agreement, as amended, has $4.0 billion in commitments and now terminates on May 15, 2030.
- The 2023 five-year credit agreement, as amended, has $3.0 billion in commitments and now terminates on August 24, 2029.
- Borrowings under the new 364-day facility based on SOFR bear interest at Term SOFR plus 1.250% to 1.700% per annum, depending on Boeing's credit rating.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 1.01Entry into a Material Definitive Agreement
- 2.03Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
- 9.01Financial Statements and Exhibits
From the filing
Item 1.01. Entry into a Material Definitive Agreement. On August 24, 2026, The Boeing Company (“Boeing”) entered into a $3.0 billion, 364-day revolving credit agreement (the “364-Day Credit Agreement”) with Citibank, N.A. (“Citibank”) and JPMorgan Chase Bank, N.A. (“JPMorgan”) as joint lead arrangers and joint book managers, Citibank as administrative agent, JPMorgan as syndication agent, and a syndicate of lenders as defined in the 364-Day Credit Agreement. This facility replaces Boeing’s previous $3.0 billion, 364-day revolving credit agreement, which was scheduled to terminate on August 24, 2026. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.